EGFR and neoplasm: Although the reductions in tumor growth obtained when EGFR antagonists were administered in vivo were only partial, we believe that these findings are promising and should be further explored to determine whether different dosing or combination with chemotherapy or other targeted agents would offer additional benefits for patients.